Endocrine Abstracts

Zoledronic acid (ZA) treatment increases bone mineral density (BMD), decreases bone turnover markers and reduces the risk of fractures in patients with osteoporosis (1).Objective: Observe and quantify the changes in BMD and bone turnover markers in postmenopausal osteoporosis (PO) patients treated annually with zoledronic acid 5 mg intravenously.Material and Methods: Medical records (MR) of PO patients whom received ZA from 2007 to...

Pheochromocytoma (PCC) is a rare tumor that arises from the adrenal medulla, usually presents with headache, sweating and palpitations due to excessive catecholamine release. However, PCC may secrete neuropeptides, hormones and cytokines, such as interleukin-6 (IL-6)) resulting in unusual clinical manifestations. A 48-year-old woman with a previous history of type 1 neurofibromatosis (NF1) and hypertension was referred to discarded PCC. Laboratory tests revealed leukocytosis a...